# US 2012/0251516 A1 · Pharmaceutical composition for treating cancer comprising trypsinogen and/or chymotrypsinogen and an active agent selected from a selenium compound, a vanilloid compound and a cytoplasmic glycolysis reduction agent

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0251516 A1
- Document ID: US20120251516A1
- Status: Published application
- Kind: A1
- Application number: 13/502,917
- Filed: 2010-10-22
- Published: 2012-10-04
- Earliest claimed: 2009-10-22
- Assignees: Propanc Pty Ltd
- Inventors: Julian Norman Kenyon; Paul Rodney Clayton; David Tosh; Fernando Felquer; Ralf Brandt
- Web page: https://patentgrep.com/patent/US20120251516A1

## CPC

- A61K 33/04: Sulfur, selenium or tellurium; Compounds thereof
- A61K 31/095: Sulfur, selenium, or tellurium compounds, e.g. thiols
- A61K 31/21: Esters, e.g. nitroglycerine, selenocyanates
- A61K 38/47: acting on glycosyl compounds (3.2), e.g. cellulases, lactases
- A61K 38/4826: {Trypsin (3.4.21.4) Chymotrypsin (3.4.21.1)}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K 2300/00: Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention generally relates to pharmaceutical compositions containing a protease proenzyme and use thereof for treating cancer. The pharmaceutical compositions are directed to compositions comprising a protease proenzyme and an active agent, the composition being capable of providing a multi-functional approach for treating cancer. The pharmaceutical compositions are also directed to compositions comprising a first and a second protease proenzyme capable of activation at or near a surface of a tumour cell to enhance cell-to-cell adhesion of tumour cells, effect proteolysis of tumour cells, or induce tumour cell apoptosis, differentiation or immunorecognition, wherein the first protease proenzyme is chymotrypsinogen and the second protease proenzyme is trypsinogen. The pharmaceutical compositions are also directed to compositions comprising a first and second active agent each capable of inducing intracellular activity in tumour cells.

## Claims

### Claim 1

A pharmaceutical composition comprising a protease proenzyme and an active agent, the composition providing a multi-functional approach for treating cancer, wherein the protease proenzyme is selected from at least one of trypsinogen and chymotrypsinogen, and the active agent is selected from at least one of a selenium compound, a vanilloid compound and a cytoplasmic glycolysis reduction agent, and optionally a glycoside hydrolase.

### Claim 2 (depends on 1)

The pharmaceutical composition of claim 1, wherein the protease proenzyme is trypsinogen and chymotrypsinogen.

### Claim 3 (depends on 1)

The pharmaceutical composition of claim 1, wherein the weight ratio of chymotrypsinogen:trypsinogen is in the range of between 4:1 to 8:1.

### Claim 4 (depends on 3)

The pharmaceutical composition of claim 3, wherein the weight ratio of chymotrypsinogen:trypsinogen is in the range of between 5:1 to 7:1.

### Claim 5 (depends on 4)

The pharmaceutical composition of claim 4, wherein the weight ratio of chymotrypsinogen:trypsinogen is 6:1.

### Claim 6 (depends on 1)

The pharmaceutical composition of claim 1, wherein the selenium compound is a compound of Formula I or Formula II:
or a pharmaceutically acceptable salt thereof, wherein:
R1 and R3 are each independently selected from H, OH, —C(O)H, —C(O)OH, —C(O)—OR5, C1-4 alkyl and C2-6 alkenyl, wherein C1-4 alkyl and C2-6 alkenyl are optionally substituted with 0-3 substituents independently selected from halogen, OH, —NH2, —C(O)OH, and —C(O)—OR5;
R2 and R4 are each independently selected from H, OH, —C(O)H, —C(O)OH, —C(O)—OR5, C1-12alkyl and C2-12alkenyl, wherein C1-12alkyl and C2-12alkenyl are optionally interrupted with one or more groups selected from —NH—, —N(C1-4alkyl)-, —NH(CO)—, C(O)—, —C(O)O—, —O— and —C(NH2)H—C(O)O—, and optionally substituted with 0-3 substituents independently selected from halogen, —NH2, —OH, —C1-4alkyl, —C(O)OH, —C(O)H, —C(O)—OR5, —N(C1-4alkyl)H, —N(C1-4alkyl)2, —C(NH2)H—C(O)OH, cycloalkyl, cycloalkenyl and aryl; and
wherein R5 is selected from alkyl, alkenyl, cycloalkyl and cycloalkenyl.

### Claim 7 (depends on 6)

The pharmaceutical composition of claim 6, wherein R1 and R3 are each independently selected from H, OH and C1-4alkyl.

### Claim 8 (depends on 6)

The pharmaceutical composition of claim 6, wherein R2 and R4 are each independently selected from H, OH and —C1-6alkyl —C(NH2)H—C(O)OH.

### Claim 9 (depends on 1)

The pharmaceutical composition of claim 1, wherein the selenium compound is methylselenocysteine or a pharmaceutically acceptable salt thereof.

### Claim 10 (depends on 1)

The pharmaceutical composition of claim 1, wherein the vanilloid compound is a compound of Formula III:
or a pharmaceutically acceptable salt thereof, wherein:
R1 and R2 are each independently selected from H, OH, OCH3, C(O)H, OC2-6alkyl, OC2-6alkenyl, SH, SC1-6alkyl, NH2, NHC1-6alkyl and N(C1-6alkyl)2;
R3 and R4 are each independently selected from H, C1-20alkyl, C2-20alkenyl and C2-20alkynyl, wherein the C1-20alkyl, C2-20alkenyl and C2-20alkynyl, are optionally interrupted with one or more groups selected from —NR6—, —NH(CO)—, C(O)—, —C(O)O—, —O—, —C(NR6R6)H—C(O)O—, —C(S)—, —C(S)NR6— and —NR6—C(S)—NR6, and optionally substituted with 0-3 substituents independently selected from halogen, —NH2, —OH, —C1-4alkyl, —C(O)OH, —C(O)OR5, —C(O)H, —N(C1-4alkyl)H, —N(C1-4alkyl)2, —C(NH2)H—C(O)OH, —C(S)—, optionally substituted cycloalkyl, optionally substituted cycloalkenyl and optionally substituted aryl; and
wherein R5 is selected from alkyl, alkenyl, cycloalkyl, cycloalkenyl; R6 is selected from H, C1-6alkyl; and R3 and R4 may be joined to form an optionally substituted unsaturated or saturated ring having from 3 to 8 carbon atoms in the ring including from 0 to 3 heteroatoms selected from O, S and N.

### Claim 11 (depends on 10)

The pharmaceutical composition of claim 10, wherein:
R1 and R2 are each independently selected from OH, C(O)H and OCH3;
R3 is selected from H, C1-20alkyl, C2-20alkenyl and C2-20alkynyl, wherein the C1-20alkyl, C2-20alkenyl and C2-20alkynyl, are optionally interrupted with one or more groups selected from —NR6—, —NH(CO)—, C(O)—, —C(O)O—, —O—, —C(NR6R6)H—C(O)O—, —C(S)—, —C(S)NR6— and —NR6—C(S)—NR6, and optionally substituted with 0-3 substituents independently selected from halogen, —NH2, —OH, —C1-4alkyl, —C(O)OH, —C(O)OR5, —C(O)H, —N(C1-4alkyl)H, —N(C1-4alkyl)2, —C(NH2)H—C(O)OH, —C(S)—, optionally substituted cycloalkyl, optionally substituted cycloalkenyl and optionally substituted aryl; and
R4 is H.

### Claim 12 (depends on 10)

The pharmaceutical composition of claim 10, wherein R3 is selected from —C1-4alkyl-NH—C(O)—C1-12alkenyl, —C1-4alkyl-NH—C(O)—C1-12alkyl, —C1-4alkyl-O—C(O)—C1-12alkenyl and —C1-4alkyl-O—C(O)—C1-12alkyl.

### Claim 13 (depends on 1)

The pharmaceutical composition of claim 1, wherein the vanilloid compound is selected from capsiate, namely 4-hydroxy-3-methoxybenzyl(E)-8-methyl-6-nonenoate.

### Claim 14 (depends on 1)

The pharmaceutical composition of claim 1, wherein the glycoside hydrolase is α-amylase.

### Claim 15 (depends on 1)

The pharmaceutical composition of claim 1, wherein the cytoplasmic glycolysis reduction agent is 2-deoxy-D-glucose.

### Claim 16 (depends on 1)

The pharmaceutical composition of claim 1, wherein the active agent is selected from at least one of the group consisting of methylselenocysteine, capsiate, α-amylase, and 2-deoxy-D-glucose.

### Claim 17 (depends on 16)

The pharmaceutical composition of claim 16, wherein the active agent consists of methylselenocysteine, capsiate, α-amylase and 2-deoxy-D-glucose.

### Claim 18

A pharmaceutical composition comprising a first and a second protease proenzyme capable of activation at or near a surface of a tumour cell to enhance cell-to-cell adhesion of tumour cells, effect proteolysis of tumour cells, or induce tumour cell apoptosis, differentiation or immunorecognition, wherein the first protease proenzyme is chymotrypsinogen and the second protease proenzyme is trypsinogen, and the weight ratio of chymotrypsinogen:trypsinogen is in the range of between 4:1 to 8:1.

### Claim 19 (depends on 18)

The pharmaceutical composition of claim 18, wherein the weight ratio of chymotrypsinogen:trypsinogen is in the range of between 5:1 to 7:1.

### Claim 20 (depends on 19)

The pharmaceutical composition of claim 19, wherein the weight ratio of chymotrypsinogen:trypsinogen is 6:1.

### Claim 21

(canceled)

### Claim 22

A pharmaceutical composition comprising a first and second active agent each capable of inducing intracellular activity in tumour cells, wherein the first active agent is a selenium compound and the second active agent is a cytoplasmic glycolysis reduction agent.

### Claim 23

(canceled)

### Claim 24 (depends on 22)

The pharmaceutical composition of claim 22, further comprising a protease proenzyme selected from at least one of trypsinogen and chymotrypsinogen.

### Claim 25 (depends on 22)

The pharmaceutical composition of claim 22, further comprising an active agent selected from a vanilloid compound and a glycoside hydrolase.

### Claim 26 (depends on 1)

An agent for treating cancer, wherein the agent comprises a protease proenzyme and an active agent, which together are capable of providing a multi-functional approach for treating cancer, wherein the protease proenzyme and the active agent are as defined according to claim 1.

### Claim 27 (depends on 1)

Use of a protease proenzyme in the manufacture of a medicament comprising an active agent for treating cancer, wherein the protease proenzyme and the active agent are as defined according to claim 1.

### Claim 28 (depends on 1)

Use of an active agent in the manufacture of a medicament comprising a protease proenzyme for treating cancer, wherein the protease proenzyme and the active agent are as defined according to claim 1.

### Claim 29 (depends on 1)

Use of a protease proenzyme and an active agent in the manufacture of a medicament for treating cancer, wherein the protease proenzyme and the active agent are as defined according to claim 1.

### Claim 30 (depends on 1)

Use of a protease proenzyme in the manufacture of a medicament for treating cancer in a subject being treated with an active agent, wherein the active agent and protease proenzyme together are capable of effecting tumour cells, and optionally wherein the active agent is capable of inducing intracellular activity to enhance the effect of the protease proenzyme, and wherein the protease proenzyme and the active agent are as defined according to claim 1.

### Claim 31 (depends on 1)

Use of an active agent in the manufacture of a medicament for treating cancer in a subject being treated with a protease proenzyme, wherein the active agent and protease proenzyme together are capable of effecting tumour cells, and optionally wherein the active agent is capable of inducing intracellular activity to enhance the effect of the protease proenzyme, and wherein the protease proenzyme and the active agent are as defined according to claim 1.

### Claim 32 (depends on 1)

A method of treating cancer comprising administering to a subject a therapeutically effective amount of a protease proenzyme and an active agent, wherein the protease proenzyme and the active agent are as defined according to claim 1.

### Claim at position 33

-35. (canceled)

### Claim 36 (depends on 18)

A method of treating cancer comprising administering to a subject a therapeutically effective amount of the pharmaceutical composition according to claim 18.

### Claim 37 (depends on 1)

A suppository comprising a therapeutically effective amount of the pharmaceutical composition of claim 1.
